PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 
DelveInsight

Press Release


Receive press releases from DelveInsight: By Email RSS Feeds:

Phosphoinositide 3-Kinase (PI3k) Inhibitors - Pipeline Insights, 2016


DelveInsight, the leading market research and consulting company has added new report Phosphoinositide 3-Kinase (PI3k) Inhibitors Pipeline Insights, 2016 to its portfolio.

Delhi, India, July 24, 2016 --(PR.com)-- The report provides information on the therapeutic development based on the Phosphoinositide 3-Kinase (PI3k) Inhibitors across 40+ pipeline drugs and 20+ companies active in this field. DelevInsight's Report also provides the comparative analysis of Phosphoinositide 3-Kinase (PI3k) Inhibitors related drugs at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also highlights the discontinued and inactive projects in pipeline.

Phosphoinositide 3-Kinase (PI3k) Inhibitors - Competitive Landscape, Technology and Pipeline Analysis, 2016 comprehensively includes:

• In-depth analysis of the pipeline assets across this mechanism of action.
• Insights on 40+ products with 20+ companies which are active in this field.
• R&D activities and technologies used along with the pipeline molecules in development.
• Information related to collaborations, in-licensing and out-licensing deals.
• Stages of development of pipeline molecules.
• Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.
• Highlights the discontinued and inactive projects in pipeline.

Phosphoinositide 3-Kinase (PI3k) Inhibitors - Competitive Landscape, Technology and Pipeline Analysis, 2016 Report envisage Pipeline Intelligence by identifying the key players along with their potential pipeline molecule. Therefore DelveInsight's report on PI3k inhibitors helps to optimize portfolio by creating effective counter-strategies to gain competitive and therapeutic advantage in global Pharma market. In addition, it assesses the major market drivers and barriers in development of Pipeline molecules which helps to understand market for collaborations and licensing deals.

DelveInsight is offering the Report at a price of USD 1,750 as a single user license, USD 3,500 as a site license and USD 5,250 as a Global/Enterprise License.

For more information on Pipeline Insight Reports, email at info@delveInsight.com

About Us:

DelveInsight is a leading Business Consulting and Market Research Firm. We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.
Contact Information
DelveInsight
Neelaksh Dani
+91-11-4568 9769
Contact
www.delveinsight.com

Click here to view the list of recent Press Releases from DelveInsight
Promote Your Business